Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Endothelial Nitric Oxide Synthase Traffic Inducer (NOSTRIN) is a Negative Regulator of Disease Aggressiveness in Pancreatic Cancer.

Wang J, Yang S, He P, Schetter AJ, Gaedcke J, Ghadimi BM, Ried T, Yfantis HG, Lee DH, Gaida MM, Hanna N, Alexander HR, Hussain SP.

Clin Cancer Res. 2016 Dec 15;22(24):5992-6001. Epub 2016 Jul 8.

2.

A Two-Gene Prognostic Classifier for Early-Stage Lung Squamous Cell Carcinoma in Multiple Large-Scale and Geographically Diverse Cohorts.

Noro R, Ishigame T, Walsh N, Shiraishi K, Robles AI, Ryan BM, Schetter AJ, Bowman ED, Welsh JA, Seike M, Gemma A, Skaug V, Mollerup S, Haugen A, Yokota J, Kohno T, Harris CC.

J Thorac Oncol. 2017 Jan;12(1):65-76. doi: 10.1016/j.jtho.2016.08.141. Epub 2016 Sep 6.

3.

Inducible nitric oxide synthase enhances disease aggressiveness in pancreatic cancer.

Wang J, He P, Gaida M, Yang S, Schetter AJ, Gaedcke J, Ghadimi BM, Ried T, Yfantis H, Lee D, Weiss JM, Stauffer J, Hanna N, Alexander HR, Hussain SP.

Oncotarget. 2016 Aug 16;7(33):52993-53004. doi: 10.18632/oncotarget.10323.

4.

An Integrated Prognostic Classifier for Stage I Lung Adenocarcinoma Based on mRNA, microRNA, and DNA Methylation Biomarkers.

Robles AI, Arai E, Mathé EA, Okayama H, Schetter AJ, Brown D, Petersen D, Bowman ED, Noro R, Welsh JA, Edelman DC, Stevenson HS, Wang Y, Tsuchiya N, Kohno T, Skaug V, Mollerup S, Haugen A, Meltzer PS, Yokota J, Kanai Y, Harris CC.

J Thorac Oncol. 2015 Jul;10(7):1037-48. doi: 10.1097/JTO.0000000000000560.

5.

Increased microRNA-34b and -34c predominantly expressed in stromal tissues is associated with poor prognosis in human colon cancer.

Hiyoshi Y, Schetter AJ, Okayama H, Inamura K, Anami K, Nguyen GH, Horikawa I, Hawkes JE, Bowman ED, Leung SY, Harris CC.

PLoS One. 2015 Apr 20;10(4):e0124899. doi: 10.1371/journal.pone.0124899. eCollection 2015.

6.

Identification of a metastasis-specific MicroRNA signature in human colorectal cancer.

Hur K, Toiyama Y, Schetter AJ, Okugawa Y, Harris CC, Boland CR, Goel A.

J Natl Cancer Inst. 2015 Feb 6;107(3). pii: dju492. doi: 10.1093/jnci/dju492. Print 2015 Mar.

7.

The expression of four genes as a prognostic classifier for stage I lung adenocarcinoma in 12 independent cohorts.

Okayama H, Schetter AJ, Ishigame T, Robles AI, Kohno T, Yokota J, Takenoshita S, Harris CC.

Cancer Epidemiol Biomarkers Prev. 2014 Dec;23(12):2884-94. doi: 10.1158/1055-9965.EPI-14-0182. Epub 2014 Sep 21.

8.

A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.

Saito M, Shiraishi K, Matsumoto K, Schetter AJ, Ogata-Kawata H, Tsuchiya N, Kunitoh H, Nokihara H, Watanabe S, Tsuta K, Kumamoto K, Takenoshita S, Yokota J, Harris CC, Kohno T.

Clin Cancer Res. 2014 Sep 15;20(18):4784-93. doi: 10.1158/1078-0432.CCR-14-1096. Epub 2014 Aug 20.

9.

Regulation of gene expression by the BLM helicase correlates with the presence of G-quadruplex DNA motifs.

Nguyen GH, Tang W, Robles AI, Beyer RP, Gray LT, Welsh JA, Schetter AJ, Kumamoto K, Wang XW, Hickson ID, Maizels N, Monnat RJ Jr, Harris CC.

Proc Natl Acad Sci U S A. 2014 Jul 8;111(27):9905-10. doi: 10.1073/pnas.1404807111. Epub 2014 Jun 23.

10.

Druggable oncogene fusions in invasive mucinous lung adenocarcinoma.

Nakaoku T, Tsuta K, Ichikawa H, Shiraishi K, Sakamoto H, Enari M, Furuta K, Shimada Y, Ogiwara H, Watanabe S, Nokihara H, Yasuda K, Hiramoto M, Nammo T, Ishigame T, Schetter AJ, Okayama H, Harris CC, Kim YH, Mishima M, Yokota J, Yoshida T, Kohno T.

Clin Cancer Res. 2014 Jun 15;20(12):3087-93. doi: 10.1158/1078-0432.CCR-14-0107. Epub 2014 Apr 11.

11.

A key role of microRNA-29b for the suppression of colon cancer cell migration by American ginseng.

Poudyal D, Cui X, Le PM, Hofseth AB, Windust A, Nagarkatti M, Nagarkatti PS, Schetter AJ, Harris CC, Hofseth LJ.

PLoS One. 2013 Oct 9;8(10):e75034. doi: 10.1371/journal.pone.0075034. eCollection 2013.

12.

High miR-21 expression from FFPE tissues is associated with poor survival and response to adjuvant chemotherapy in colon cancer.

Oue N, Anami K, Schetter AJ, Moehler M, Okayama H, Khan MA, Bowman ED, Mueller A, Schad A, Shimomura M, Hinoi T, Aoyagi K, Sasaki H, Okajima M, Ohdan H, Galle PR, Yasui W, Harris CC.

Int J Cancer. 2014 Apr 15;134(8):1926-34. doi: 10.1002/ijc.28522. Epub 2013 Nov 8.

13.

Germline variation in NCF4, an innate immunity gene, is associated with an increased risk of colorectal cancer.

Ryan BM, Zanetti KA, Robles AI, Schetter AJ, Goodman J, Hayes RB, Huang WY, Gunter MJ, Yeager M, Burdette L, Berndt SI, Harris CC.

Int J Cancer. 2014 Mar 15;134(6):1399-407. doi: 10.1002/ijc.28457. Epub 2013 Nov 14.

14.

Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer.

Cooks T, Pateras IS, Tarcic O, Solomon H, Schetter AJ, Wilder S, Lozano G, Pikarsky E, Forshew T, Rosenfeld N, Harpaz N, Itzkowitz S, Harris CC, Rotter V, Gorgoulis VG, Oren M.

Cancer Cell. 2013 May 13;23(5):634-46. doi: 10.1016/j.ccr.2013.03.022. Erratum in: Cancer Cell. 2013 Aug 12;24(2):272. Rozenfeld, Nitzan [corrected to Rosenfeld, Nitzan].

15.

Combination of protein coding and noncoding gene expression as a robust prognostic classifier in stage I lung adenocarcinoma.

Akagi I, Okayama H, Schetter AJ, Robles AI, Kohno T, Bowman ED, Kazandjian D, Welsh JA, Oue N, Saito M, Miyashita M, Uchida E, Takizawa T, Takenoshita S, Skaug V, Mollerup S, Haugen A, Yokota J, Harris CC.

Cancer Res. 2013 Jul 1;73(13):3821-32. doi: 10.1158/0008-5472.CAN-13-0031. Epub 2013 May 2.

16.

Transcription signatures encoded by ultraconserved genomic regions in human prostate cancer.

Hudson RS, Yi M, Volfovsky N, Prueitt RL, Esposito D, Volinia S, Liu CG, Schetter AJ, Van Roosbroeck K, Stephens RM, Calin GA, Croce CM, Ambs S.

Mol Cancer. 2013 Feb 14;12:13. doi: 10.1186/1476-4598-12-13.

17.

Circulating microRNA expression profiles associated with systemic lupus erythematosus.

Carlsen AL, Schetter AJ, Nielsen CT, Lood C, Knudsen S, Voss A, Harris CC, Hellmark T, Segelmark M, Jacobsen S, Bengtsson AA, Heegaard NH.

Arthritis Rheum. 2013 May;65(5):1324-34. doi: 10.1002/art.37890.

18.

The induction of microRNA-16 in colon cancer cells by protein arginine deiminase inhibition causes a p53-dependent cell cycle arrest.

Cui X, Witalison EE, Chumanevich AP, Chumanevich AA, Poudyal D, Subramanian V, Schetter AJ, Harris CC, Thompson PR, Hofseth LJ.

PLoS One. 2013;8(1):e53791. doi: 10.1371/journal.pone.0053791. Epub 2013 Jan 7.

19.

Evolutionarily conserved protein ERH controls CENP-E mRNA splicing and is required for the survival of KRAS mutant cancer cells.

Weng MT, Lee JH, Wei SC, Li Q, Shahamatdar S, Hsu D, Schetter AJ, Swatkoski S, Mannan P, Garfield S, Gucek M, Kim MK, Annunziata CM, Creighton CJ, Emanuele MJ, Harris CC, Sheu JC, Giaccone G, Luo J.

Proc Natl Acad Sci U S A. 2012 Dec 26;109(52):E3659-67. doi: 10.1073/pnas.1207673110. Epub 2012 Dec 10.

20.

MicroRNAs and inflammation in the pathogenesis and progression of colon cancer.

Okayama H, Schetter AJ, Harris CC.

Dig Dis. 2012;30 Suppl 2:9-15. doi: 10.1159/000341882. Epub 2012 Nov 23. Review.

21.

microRNA and inflammatory gene expression as prognostic marker for overall survival in esophageal squamous cell carcinoma.

Zhao Y, Schetter AJ, Yang GB, Nguyen G, Mathé EA, Li P, Cai H, Yu L, Liu F, Hang D, Yang H, Wang XW, Ke Y, Harris CC.

Int J Cancer. 2013 Jun 15;132(12):2901-9. doi: 10.1002/ijc.27954. Epub 2012 Dec 17.

22.

MicroRNA-106b-25 cluster expression is associated with early disease recurrence and targets caspase-7 and focal adhesion in human prostate cancer.

Hudson RS, Yi M, Esposito D, Glynn SA, Starks AM, Yang Y, Schetter AJ, Watkins SK, Hurwitz AA, Dorsey TH, Stephens RM, Croce CM, Ambs S.

Oncogene. 2013 Aug 29;32(35):4139-47. doi: 10.1038/onc.2012.424. Epub 2012 Sep 17.

23.

Macrophages, nitric oxide and microRNAs are associated with DNA damage response pathway and senescence in inflammatory bowel disease.

Sohn JJ, Schetter AJ, Yfantis HG, Ridnour LA, Horikawa I, Khan MA, Robles AI, Hussain SP, Goto A, Bowman ED, Hofseth LJ, Bartkova J, Bartek J, Wogan GN, Wink DA, Harris CC.

PLoS One. 2012;7(9):e44156. doi: 10.1371/journal.pone.0044156. Epub 2012 Sep 6.

24.

Clinicopathological study of non-palpable familial breast cancer detected by screening mammography and diagnosed as DCIS.

Saito M, Matsuzaki M, Sakuma T, Katagata N, Watanabe F, Yamaguchi Y, Schetter AJ, Takenoshita S, Nomizu T.

Breast Cancer. 2014 Mar;21(2):140-5. doi: 10.1007/s12282-012-0389-3. Epub 2012 Aug 9.

PMID:
22875640
25.

The rectal cancer microRNAome--microRNA expression in rectal cancer and matched normal mucosa.

Gaedcke J, Grade M, Camps J, Søkilde R, Kaczkowski B, Schetter AJ, Difilippantonio MJ, Harris CC, Ghadimi BM, Møller S, Beissbarth T, Ried T, Litman T.

Clin Cancer Res. 2012 Sep 15;18(18):4919-30. Epub 2012 Jul 31.

26.

Functional interaction of tumor suppressor DLC1 and caveolin-1 in cancer cells.

Du X, Qian X, Papageorge A, Schetter AJ, Vass WC, Liu X, Braverman R, Robles AI, Lowy DR.

Cancer Res. 2012 Sep 1;72(17):4405-16. doi: 10.1158/0008-5472.CAN-12-0777. Epub 2012 Jun 12.

27.

The role of microRNAs in colorectal cancer.

Schetter AJ, Okayama H, Harris CC.

Cancer J. 2012 May-Jun;18(3):244-52. doi: 10.1097/PPO.0b013e318258b78f. Review.

28.

Tumor suppressor p53 (TP53) at the crossroads of the exposome and the cancer genome.

Schetter AJ, Harris CC.

Proc Natl Acad Sci U S A. 2012 May 22;109(21):7955-6. doi: 10.1073/pnas.1205457109. Epub 2012 May 16. No abstract available.

29.

KIF5B-RET fusions in lung adenocarcinoma.

Kohno T, Ichikawa H, Totoki Y, Yasuda K, Hiramoto M, Nammo T, Sakamoto H, Tsuta K, Furuta K, Shimada Y, Iwakawa R, Ogiwara H, Oike T, Enari M, Schetter AJ, Okayama H, Haugen A, Skaug V, Chiku S, Yamanaka I, Arai Y, Watanabe S, Sekine I, Ogawa S, Harris CC, Tsuda H, Yoshida T, Yokota J, Shibata T.

Nat Med. 2012 Feb 12;18(3):375-7. doi: 10.1038/nm.2644.

PMID:
22327624
30.

Alterations of microRNAs contribute to colon carcinogenesis.

Schetter AJ, Harris CC.

Semin Oncol. 2011 Dec;38(6):734-42. doi: 10.1053/j.seminoncol.2011.08.009. Review.

31.

MicroRNAs as molecular classifiers for cancer.

Schetter AJ, Harris CC.

Cell Cycle. 2011 Sep 1;10(17):2827-8. Epub 2011 Sep 1. No abstract available.

32.

Tumor suppressor miR-22 determines p53-dependent cellular fate through post-transcriptional regulation of p21.

Tsuchiya N, Izumiya M, Ogata-Kawata H, Okamoto K, Fujiwara Y, Nakai M, Okabe A, Schetter AJ, Bowman ED, Midorikawa Y, Sugiyama Y, Aburatani H, Harris CC, Nakagama H.

Cancer Res. 2011 Jul 1;71(13):4628-39. doi: 10.1158/0008-5472.CAN-10-2475. Epub 2011 May 12.

33.

Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer.

Heegaard NH, Schetter AJ, Welsh JA, Yoneda M, Bowman ED, Harris CC.

Int J Cancer. 2012 Mar 15;130(6):1378-86. doi: 10.1002/ijc.26153. Epub 2011 Aug 26.

34.

Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis.

Cheng H, Zhang L, Cogdell DE, Zheng H, Schetter AJ, Nykter M, Harris CC, Chen K, Hamilton SR, Zhang W.

PLoS One. 2011 Mar 17;6(3):e17745. doi: 10.1371/journal.pone.0017745.

35.

The association of microRNA expression with prognosis and progression in early-stage, non-small cell lung adenocarcinoma: a retrospective analysis of three cohorts.

Saito M, Schetter AJ, Mollerup S, Kohno T, Skaug V, Bowman ED, Mathé EA, Takenoshita S, Yokota J, Haugen A, Harris CC.

Clin Cancer Res. 2011 Apr 1;17(7):1875-82. doi: 10.1158/1078-0432.CCR-10-2961. Epub 2011 Feb 24.

36.

MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma.

Voortman J, Goto A, Mendiboure J, Sohn JJ, Schetter AJ, Saito M, Dunant A, Pham TC, Petrini I, Lee A, Khan MA, Hainaut P, Pignon JP, Brambilla E, Popper HH, Filipits M, Harris CC, Giaccone G.

Cancer Res. 2010 Nov 1;70(21):8288-98. doi: 10.1158/0008-5472.CAN-10-1348. Epub 2010 Oct 26.

37.

Inflammatory and microRNA gene expression as prognostic classifier of Barrett's-associated esophageal adenocarcinoma.

Nguyen GH, Schetter AJ, Chou DB, Bowman ED, Zhao R, Hawkes JE, Mathé EA, Kumamoto K, Zhao Y, Budhu A, Hagiwara N, Wang XW, Miyashita M, Casson AG, Harris CC.

Clin Cancer Res. 2010 Dec 1;16(23):5824-34. doi: 10.1158/1078-0432.CCR-10-1110. Epub 2010 Oct 14.

38.

Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways.

Schetter AJ, Heegaard NH, Harris CC.

Carcinogenesis. 2010 Jan;31(1):37-49. doi: 10.1093/carcin/bgp272. Epub 2009 Dec 2. Review.

39.

MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival.

Mathé EA, Nguyen GH, Bowman ED, Zhao Y, Budhu A, Schetter AJ, Braun R, Reimers M, Kumamoto K, Hughes D, Altorki NK, Casson AG, Liu CG, Wang XW, Yanaihara N, Hagiwara N, Dannenberg AJ, Miyashita M, Croce CM, Harris CC.

Clin Cancer Res. 2009 Oct 1;15(19):6192-200. doi: 10.1158/1078-0432.CCR-09-1467. Epub 2009 Sep 29.

40.

Plasma microRNAs: a potential biomarker for colorectal cancer?

Schetter AJ, Harris CC.

Gut. 2009 Oct;58(10):1318-9. doi: 10.1136/gut.2009.176875. No abstract available.

PMID:
19749133
41.

Association of inflammation-related and microRNA gene expression with cancer-specific mortality of colon adenocarcinoma.

Schetter AJ, Nguyen GH, Bowman ED, Mathé EA, Yuen ST, Hawkes JE, Croce CM, Leung SY, Harris CC.

Clin Cancer Res. 2009 Sep 15;15(18):5878-87. doi: 10.1158/1078-0432.CCR-09-0627. Epub 2009 Sep 8.

42.

p53 isoforms Delta133p53 and p53beta are endogenous regulators of replicative cellular senescence.

Fujita K, Mondal AM, Horikawa I, Nguyen GH, Kumamoto K, Sohn JJ, Bowman ED, Mathe EA, Schetter AJ, Pine SR, Ji H, Vojtesek B, Bourdon JC, Lane DP, Harris CC.

Nat Cell Biol. 2009 Sep;11(9):1135-42. doi: 10.1038/ncb1928. Epub 2009 Aug 23.

43.

MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers.

Seike M, Goto A, Okano T, Bowman ED, Schetter AJ, Horikawa I, Mathe EA, Jen J, Yang P, Sugimura H, Gemma A, Kudoh S, Croce CM, Harris CC.

Proc Natl Acad Sci U S A. 2009 Jul 21;106(29):12085-90. doi: 10.1073/pnas.0905234106. Epub 2009 Jul 13.

44.

MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma.

Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, Yuen ST, Chan TL, Kwong DL, Au GK, Liu CG, Calin GA, Croce CM, Harris CC.

JAMA. 2008 Jan 30;299(4):425-36. doi: 10.1001/jama.299.4.425.

45.

Association of Epstein-Barr virus antibody levels with precancerous gastric lesions in a high-risk cohort.

Schetter AJ, You WC, Lennette ET, Gail MT, Rabkin CS.

Cancer Sci. 2008 Feb;99(2):350-4. doi: 10.1111/j.1349-7006.2007.00668.x. Epub 2008 Jan 14.

46.

Predictive models of molecular machines involved in Caenorhabditis elegans early embryogenesis.

Gunsalus KC, Ge H, Schetter AJ, Goldberg DS, Han JD, Hao T, Berriz GF, Bertin N, Huang J, Chuang LS, Li N, Mani R, Hyman AA, Sönnichsen B, Echeverri CJ, Roth FP, Vidal M, Piano F.

Nature. 2005 Aug 11;436(7052):861-5.

47.

New genes with roles in the C. elegans embryo revealed using RNAi of ovary-enriched ORFeome clones.

Fernandez AG, Gunsalus KC, Huang J, Chuang LS, Ying N, Liang HL, Tang C, Schetter AJ, Zegar C, Rual JF, Hill DE, Reinke V, Vidal M, Piano F.

Genome Res. 2005 Feb;15(2):250-9.

48.

Gene clustering based on RNAi phenotypes of ovary-enriched genes in C. elegans.

Piano F, Schetter AJ, Morton DG, Gunsalus KC, Reinke V, Kim SK, Kemphues KJ.

Curr Biol. 2002 Nov 19;12(22):1959-64.

49.

Integrating interactome, phenome, and transcriptome mapping data for the C. elegans germline.

Walhout AJ, Reboul J, Shtanko O, Bertin N, Vaglio P, Ge H, Lee H, Doucette-Stamm L, Gunsalus KC, Schetter AJ, Morton DG, Kemphues KJ, Reinke V, Kim SK, Piano F, Vidal M.

Curr Biol. 2002 Nov 19;12(22):1952-8.

50.

RNAi analysis of genes expressed in the ovary of Caenorhabditis elegans.

Piano F, Schetter AJ, Mangone M, Stein L, Kemphues KJ.

Curr Biol. 2000 Dec 14-28;10(24):1619-22.

Supplemental Content

Loading ...
Support Center